Affinage

SLAMF7

SLAM family member 7 · UniProt Q9NQ25

Length
335 aa
Mass
37.4 kDa
Annotated
2026-04-28
100 papers in source corpus 18 papers cited in narrative 18 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SLAMF7 is a homophilic, self-ligand SLAM-family immunoreceptor that functions as a context-dependent activating or inhibitory receptor on NK cells, macrophages, B cells, and myeloma cells, with signaling outcome determined by the availability of the adaptor EAT-2. In EAT-2-expressing NK cells, SLAMF7 ligation costimulates cytotoxicity via calcium signaling and NKG2D upregulation, whereas in EAT-2-negative cells (T cells, macrophages, myeloma cells) SLAMF7 recruits SHIP1 through phosphorylated tyrosine residues (Y261, Y304) — dependent on CD45-activated Src kinases — and forms a trimolecular complex with TRAF6, suppressing K63 ubiquitination of TRAF6 and thereby attenuating MAPK/NF-κB signaling (PMID:19151721, PMID:25312647, PMID:36749634, PMID:38484085). On myeloma cells, SLAMF7 promotes adhesion to bone marrow stroma, activates ERK/AKT/STAT3 survival pathways partly through c-maf, and its soluble ectodomain signals back via SHP-2/ERK; on macrophages, SLAMF7 engagement can drive a superactivated inflammatory state with TNF-α autocrine amplification regulated by IFN-γ and m6A epitranscriptomic modification (PMID:19196658, PMID:31358854, PMID:35148199, PMID:37827106).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2002 Medium

    Establishing that SLAMF7 is a homophilic receptor answered the fundamental question of ligand identity: SLAMF7 binds itself rather than a heterologous ligand, and this self-interaction activates NK cell cytotoxicity.

    Evidence Recombinant CS1-Ig fusion binding to CS1-transfected cells and redirected NK cytotoxicity assay

    PMID:12213321

    Open questions at the time
    • Binding affinity not quantified
    • Homophilic interaction not confirmed in vivo
    • Downstream signaling pathway not identified
  2. 2004 Medium

    Identification of two splice isoforms (CS1-L with ITSMs, CS1-S without) resolved how SLAMF7 can couple to different signaling outcomes, and the finding that SAP associates with CS1-L linked SLAMF7 to the canonical SLAM-family adaptor machinery.

    Evidence Isoform reconstitution in RNK-16 NK cells with redirected cytotoxicity, calcium flux, and SAP co-immunoprecipitation

    PMID:15368295

    Open questions at the time
    • EAT-2 role not yet tested
    • ITSM phosphorylation sites not individually mapped
    • Physiological ratio of isoforms unclear
  3. 2006 Medium

    Demonstrating that SLAMF7 homophilic engagement drives NK killing of MHC-I-negative targets established SLAMF7 as an activating receptor participating in 'missing-self' recognition.

    Evidence Anti-CRACC blocking antibodies in NK cytotoxicity assays against MHC-I-negative targets

    PMID:16410313

    Open questions at the time
    • Relative contribution vs. NKG2D/NKp46 not quantified
    • In vivo relevance not tested
  4. 2007 Medium

    Two studies expanded SLAMF7 function beyond NK cells: on myeloma cells, SLAMF7 localized to uropods and mediated adhesion to bone marrow stroma; on B cells, SLAMF7 ligation induced proliferation through an autocrine cytokine loop involving TNF, lymphotoxin-α, and IL-14.

    Evidence siRNA knockdown adhesion assays in MM cells; anti-CS1 mAb stimulation with cytokine neutralization in primary B cells

    PMID:17878365 PMID:17906076

    Open questions at the time
    • Adhesion receptor partners on stroma not identified
    • Autocrine cytokine loop not confirmed in vivo
    • Signaling cascade in B cells not mapped
  5. 2009 High

    Genetic ablation of SLAMF7 in mice revealed that EAT-2, not SAP, is the critical adaptor for activating signaling, and in cells lacking EAT-2 SLAMF7 is inhibitory — a pivotal switch mechanism explaining cell-type-specific outcomes. Concurrently, SLAMF7 was shown to promote myeloma cell survival via ERK/AKT/STAT3 and c-maf.

    Evidence CRACC-knockout mouse NK/T cell assays; lentiviral knockdown/overexpression in MM cells with signaling analysis and xenograft models

    PMID:19151721 PMID:19196658

    Open questions at the time
    • Structure of EAT-2–SLAMF7 complex unknown
    • Identity of inhibitory effector in EAT-2-negative cells not yet determined
  6. 2013 Medium

    The EAT-2-dependent activation model was validated in the therapeutic context of elotuzumab: differential EAT-2 expression (present in NK cells, absent in MM cells) explains why elotuzumab activates NK cells against MM without triggering fratricidal killing of NK cells.

    Evidence NK activation and ADCC assays comparing EAT-2-expressing NK cells with EAT-2-negative MM cells

    PMID:24162108

    Open questions at the time
    • Other inhibitory adaptors in MM cells not examined
    • Patient heterogeneity in EAT-2 expression not addressed
  7. 2014 High

    SHIP1 was identified as the inhibitory effector recruited to SLAMF7 tyrosine 261, requiring CD45-activated Src kinases for SLAMF7 phosphorylation — explaining why MM cells (which lack CD45) cannot engage this inhibitory circuit and are therefore vulnerable to elotuzumab-mediated NK attack.

    Evidence Y261 mutagenesis, SHIP1 co-immunoprecipitation, Src kinase inhibitors, CD45-deficient NK cells

    PMID:25312647

    Open questions at the time
    • Crystal structure of SLAMF7–SHIP1 interface not resolved
    • Role of Y304 not yet examined
  8. 2017 High

    Elotuzumab was shown to costimulate NK cells through a CD16-independent mechanism requiring the SLAMF7 cytoplasmic domain, demonstrating that SLAMF7 provides a direct activating signal synergizing with NKp46/NKG2D co-engagement.

    Evidence F(ab')2 and Fc-mutant antibodies, CD16-negative NK-92 cells, cytoplasmic domain deletion constructs, calcium mobilization

    PMID:28932638

    Open questions at the time
    • Proximal signaling intermediates downstream of SLAMF7 cytoplasmic domain in this costimulatory mode not identified
  9. 2019 Medium

    Soluble SLAMF7 shed from MM cells was found to signal back through surface SLAMF7 via SHP-2/ERK, establishing an autocrine growth loop; additionally, IKZF1 (Ikaros) was identified as a transcriptional activator of SLAMF7, explaining how lenalidomide downregulates SLAMF7 through Ikaros degradation.

    Evidence Recombinant sSLAMF7 treatment, phospho-SHP-2/ERK analysis, SLAMF7 promoter analysis, IMiD treatment with IKZF1 degradation readout

    PMID:31358854

    Open questions at the time
    • Protease responsible for SLAMF7 shedding not identified
    • sSLAMF7 levels as clinical biomarker not validated
  10. 2022 Medium

    Two studies broadened SLAMF7's physiological scope: on macrophages, SLAMF7 engagement drives a superactivated inflammatory state with TNF-α autocrine amplification regulated by IFN-γ; on B cells, SLAMF7 knockout increases susceptibility to EAE via exaggerated T cell activation, indicating a B cell-intrinsic regulatory role in CNS autoimmunity.

    Evidence RNA-seq and antibody engagement of synovial macrophages; SLAMF7-KO mice with EAE, adoptive B cell transfer, B-T co-culture

    PMID:35148199 PMID:36199066

    Open questions at the time
    • Signaling pathway downstream of SLAMF7 in B cell regulation of T cells not mapped
    • Whether macrophage superactivation uses EAT-2 or SHIP1 pathway unclear
  11. 2023 High

    The SLAMF7–SHIP1 inhibitory axis was extended to macrophage innate signaling: SLAMF7 forms a trimolecular complex with SHIP1 and TRAF6, suppressing K63 ubiquitination of TRAF6 to attenuate TLR-dependent MAPK/NF-κB activation, establishing SLAMF7 as a negative regulator of innate inflammation.

    Evidence Co-IP of SLAMF7/SHIP1/TRAF6, K63-ubiquitination assays, tyrosine and phosphatase-dead mutants, sepsis mouse models

    PMID:36749634

    Open questions at the time
    • How SLAMF7 superactivation (pro-inflammatory) and SHIP1/TRAF6 inhibition (anti-inflammatory) are balanced in the same macrophage not resolved
  12. 2023 Medium

    Epitranscriptomic regulation of SLAMF7 was discovered: ALKBH5-mediated m6A demethylation destabilizes Slamf7 mRNA, and ALKBH5 inhibition increases SLAMF7 expression in macrophages, promoting autophagy and reducing pro-inflammatory cytokine secretion.

    Evidence MeRIP assay, ALKBH5 inhibition, mRNA stability and autophagy/cytokine assays in macrophages

    PMID:37827106

    Open questions at the time
    • Specific m6A sites on SLAMF7 mRNA not mapped
    • METTL14 writer contribution not fully delineated
    • In vivo relevance of epitranscriptomic regulation not tested
  13. 2024 High

    A second ITSM tyrosine (Y304) was shown to recruit SHIP1 via the SHB adaptor in hepatocellular carcinoma cells, inhibiting TRAF6 ubiquitination, MAPK/ATF2 signaling, and CCL2 transcription, thereby controlling macrophage recruitment and polarization in the tumor microenvironment.

    Evidence Y304 mutagenesis, co-IP of SLAMF7-SHB-SHIP1 complex, TRAF6 ubiquitination assay, liver-specific Slamf7 KO mice

    PMID:38484085

    Open questions at the time
    • Relative contributions of Y261 vs. Y304 in different cell types not compared
    • Structural basis of SHB vs. direct SHIP1 recruitment not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include how the opposing pro-inflammatory (superactivation) and anti-inflammatory (SHIP1/TRAF6) functions of SLAMF7 are coordinated within the same macrophage, the structural basis of the SLAMF7-EAT-2 vs. SLAMF7-SHIP1 signaling switch, and whether epitranscriptomic regulation of SLAMF7 is relevant in vivo.
  • No structural data for any SLAMF7 signaling complex
  • Mechanism integrating activating vs. inhibitory outcomes in a single cell type unknown
  • In vivo significance of m6A regulation of SLAMF7 untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0098772 molecular function regulator activity 4 GO:0098631 cell adhesion mediator activity 3
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-168256 Immune System 5 R-HSA-1500931 Cell-Cell communication 4
Partners
EAT-2SAPSHBSHIP1SHP-2TRAF6

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 CS1 (SLAMF7) is a self-ligand (homophilic receptor); recombinant CS1-Ig fusion protein bound cells transfected with CS1 but not cells expressing other CD2 family members, and soluble CS1-Ig enhanced NK cell cytolytic activity, demonstrating that homophilic CS1-CS1 interaction activates NK cell cytotoxicity. Recombinant fusion protein binding assay, redirected cytotoxicity assay with human NK cell line YT Molecular immunology Medium 12213321
2004 Two CS1 (SLAMF7) splice isoforms exist: CS1-L (containing ITSMs) and CS1-S (lacking ITSMs). CS1-L mediates activating signals (redirected cytotoxicity and calcium flux) in NK cells, whereas CS1-S does not. SAP associates with unstimulated CS1-L and dissociates upon pervanadate stimulation, linking ITSM phosphorylation state to SAP binding. cDNA transfection into rat NK cell line RNK-16, redirected cytotoxicity assay, calcium flux measurement, co-immunoprecipitation of SAP with CS1-L European journal of immunology Medium 15368295
2007 CS1 (SLAMF7) localizes to adhesion-promoting uropod membranes of polarized MM cells and mediates MM cell adhesion to bone marrow stromal cells (BMSCs); siRNA knockdown of CS1 inhibited MM cell adhesion to BMSCs. siRNA knockdown, cell adhesion assay, immunofluorescence localization Blood Medium 17906076
2007 CS1 (SLAMF7) engagement on human B lymphocytes induces proliferation through an autocrine cytokine loop involving flt3 ligand, lymphotoxin A, TNF, and IL-14; neutralizing antibodies against these cytokines abolished CS1-induced B cell proliferation. Only the CS1-L isoform is expressed on B cells. Anti-CS1 mAb stimulation of isolated B cells, cytokine microarray, quantitative RT-PCR, neutralizing antibody blockade experiments Journal of immunology Medium 17878365
2009 CRACC/SLAMF7 positively regulates NK cell function via the adaptor EAT-2 but not SAP; in the absence of EAT-2, CRACC potently inhibits NK cell function. In T cells, which lack EAT-2, CRACC is inhibitory. Established using CRACC-deficient mice. CRACC-deficient mouse generation, NK cell functional assays, comparison of EAT-2-expressing vs. EAT-2-deficient contexts Nature immunology High 19151721
2009 CS1 (SLAMF7) knockdown in MM cells decreased phosphorylation of ERK1/2, AKT, and STAT3, and accelerated apoptosis under serum deprivation. CS1 overexpression increased c-maf-targeted cyclin D2-dependent proliferation, integrin β7/αE-mediated adhesion to BMSCs, and VEGF-induced angiogenesis in vivo. Lentiviral siRNA knockdown, phospho-protein western blot, caspase activation assay, overexpression studies, murine xenograft model Blood High 19196658
2014 SLAMF7-mediated inhibition in EAT-2-negative NK cells is mediated by SHIP-1, which is recruited via tyrosine 261 of SLAMF7. This coupling requires Src kinases, which phosphorylate SLAMF7, and CD45, which activates Src kinases. MM cells lack EAT-2 and CD45, so SLAMF7 cannot trigger inhibitory SHIP-1 signaling in them, explaining why elotuzumab kills MM cells via indirect NK activation. Mutagenesis of SLAMF7 tyrosine 261, co-immunoprecipitation of SHIP-1 with SLAMF7, Src kinase inhibitor studies, CD45-deficient NK cell analysis Molecular and cellular biology High 25312647
2017 Elotuzumab activates NK cells through two mechanisms: (1) CD16 (FcγRIIIa)-dependent ADCC and (2) direct SLAMF7 ligation-dependent costimulation of calcium signaling triggered by NKp46 and NKG2D, independent of CD16. The direct costimulation requires the full cytoplasmic domain of SLAMF7 on NK cells. F(ab')2 and Fc-mutant antibody forms, CD16-negative NK-92 cell assays, calcium mobilization assays with NKp46/NKG2D co-engagement, cytoplasmic domain-deleted SLAMF7 constructs Oncoimmunology High 28932638
2019 Soluble SLAMF7 (sSLAMF7), shed from MM cells, promotes MM cell growth through homophilic interaction with surface SLAMF7 and subsequent activation of SHP-2 and ERK signaling pathways. IKZF1 (Ikaros) was identified as a transcriptional activator of the SLAMF7 gene; lenalidomide and pomalidomide downregulate SLAMF7 expression by targeting Ikaros. Recombinant sSLAMF7 treatment of MM cells, phospho-protein western blot (SHP-2, ERK), promoter analysis, lenalidomide/pomalidomide treatment with IKZF1 degradation, murine xenograft model Leukemia Medium 31358854
2019 Elotuzumab enhances SLAMF7-SLAMF7 homotypic interactions between NK cells and MM target cells in a CD16-independent manner, requiring the full cytoplasmic domain of SLAMF7 on NK cells. This costimulation is associated with upregulation of NKG2D and activated LFA-1 on NK cells, and enhanced cytotoxicity is partially reduced by NKG2D blocking. CD16-negative NK-92 cells, cytoplasmic domain-deleted SLAMF7 constructs, NKG2D blocking antibodies, degranulation/cytotoxicity assays Cancer immunology research Medium 31431433
2022 SLAMF7 engagement on macrophages drives a superactivated inflammatory state characterized by strong cytokine expression; IFN-γ is a key regulator of SLAMF7 expression on macrophages; SLAMF7 engagement induces TNF-α production which amplifies inflammation through an autocrine signaling loop. RNA-seq of synovial macrophages, SLAMF7 antibody engagement experiments, cytokine expression profiling, IFN-γ stimulation assays Science immunology Medium 35148199
2023 SLAMF7 attenuates TLR-dependent MAPK and NF-κB signaling in macrophages by cooperating with SHIP1; SLAMF7 interacts with SHIP1 and TRAF6 to inhibit K63 ubiquitination of TRAF6. Tyrosine phosphorylation sites within the SLAMF7 intracellular domain and the phosphatase domain of SHIP1 are required for the SLAMF7-SHIP1-TRAF6 interaction. Co-immunoprecipitation of SLAMF7/SHIP1/TRAF6 complex, ubiquitination assay (K63-linkage), SLAMF7 tyrosine mutants, SHIP1 phosphatase-dead mutants, sepsis mouse models Journal of Clinical Investigation High 36749634
2024 In hepatocellular carcinoma cells, SLAMF7 associates with SHB adaptor protein through its cytoplasmic tyrosine 304 site to recruit SHIP1 to SLAMF7, which then inhibits TRAF6 ubiquitination and suppresses MAPK pathway activation and CCL2 transcription, thereby regulating macrophage migration and polarization. Co-immunoprecipitation of SLAMF7-SHB-SHIP1 complex, SLAMF7 Y304 mutant, TRAF6 ubiquitination assay, CCL2 promoter/MAPK/ATF2 signaling analysis, liver-specific Slamf7 knockout mice Cancer research High 38484085
2006 CRACC (CS1/SLAMF7) engagement by its physiological self-ligand on MHC class I-negative target cells induces potent NK cell cytotoxicity; blocking CRACC engagement had no effect on NK cell proliferation or cytotoxic potential development, but CRACC-mediated killing contributes to NK cell autologous killing when inhibitory MHC class I signals are removed. Blocking antibodies against CRACC, NK cell cytotoxicity assays with MHC class I-negative targets, NK cell proliferation assays International immunology Medium 16410313
2013 Elotuzumab activates NK cells by binding to CS1/SLAMF7 on NK cells, promoting cytotoxicity against CS1+ MM target cells but not autologous CS1+ NK cells. NK cell activation by elotuzumab is dependent on differential expression of EAT-2, which is present in NK cells but absent in primary MM cells. NK cell activation assays, ADCC assays, EAT-2 expression analysis in NK cells vs. MM cells, CS1-CS1 interaction studies Cancer immunology, immunotherapy Medium 24162108
2019 Cancer cell-expressed SLAMF7 is not required for CD47 antibody-mediated phagocytosis; SLAMF7 expression on cancer cells does not impact CD47 antibody therapy or CD20 antibody rituximab-mediated phagocytosis. SLAMF7 knockdown/knockout in cancer cells, phagocytosis assays with anti-CD47 and anti-CD20 antibodies, macrophage co-culture assays Nature communications Medium 30710089
2022 SLAMF7 modulates B cell function to regulate CNS autoimmunity; SLAMF7-/- mice are more susceptible to EAE, and SLAMF7-/- B cells induce exaggerated T cell activation in co-culture. Adoptive transfer of SLAMF7-/- B cells into B cell-deficient mice increases EAE susceptibility, demonstrating B cell-dependent regulation by SLAMF7. SLAMF7 knockout mice, EAE model, adoptive transfer of B cells, B-T cell co-culture assays, spectral cytometry, scRNA-seq interactome analysis Journal of neuroinflammation Medium 36199066
2023 ALKBH5 promotes m6A modification of Slamf7 mRNA, which decreases Slamf7 mRNA stability in an m6A-dependent manner; specific inhibition of ALKBH5 increases Slamf7 expression in macrophages, and increased SLAMF7 expression promotes autophagy and reduces pro-inflammatory cytokine secretion. MeRIP assay, ALKBH5 inhibition experiments, mRNA stability assays, autophagy and cytokine secretion assays Journal of hazardous materials Medium 37827106

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 405 17906076
2013 Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer immunology, immunotherapy : CII 252 24162108
1993 Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1. The Journal of biological chemistry 249 7677996
2017 SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood 201 29089311
2020 Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nature communications 171 32385241
2015 Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 160 26631114
2017 miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1. Molecular cancer 154 28257633
2017 Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research 153 29061640
2009 Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nature immunology 147 19151721
2009 Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular cancer therapeutics 142 19723891
1994 Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. The Journal of clinical investigation 135 8282813
2021 CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene therapy 133 33846552
2002 CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Molecular immunology 110 12213321
2001 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunological reviews 109 11513145
2020 METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. European review for medical and pharmacological sciences 102 32633395
2018 Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Frontiers in immunology 101 30455698
2014 Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clinical cancer research : an official journal of the American Association for Cancer Research 100 24677374
2013 CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Critical reviews in oncology/hematology 100 23731618
1993 Mutation of putative divalent cation sites in the alpha 4 subunit of the integrin VLA-4: distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin. The Journal of cell biology 96 7691827
2018 microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 91 30021351
2014 miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. Journal of experimental & clinical cancer research : CR 91 25107371
2017 CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. American journal of cancer research 89 28861320
2008 Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. American journal of human genetics 87 18460397
2013 miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PloS one 86 23894411
2022 SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. Science immunology 81 35148199
1990 Gene encoding the major subunit of CS1 pili of human enterotoxigenic Escherichia coli. Infection and immunity 73 1977705
2014 Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Molecular and cellular biology 72 25312647
2017 The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology 68 28932638
2013 miR-19a and miR-19b overexpression in gliomas. Pathology oncology research : POR 65 23824915
2007 CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 65 17878365
2020 Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers 61 32630303
2009 CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 61 19196658
2019 Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia 60 31358854
2017 MircroRNA-19a promotes vascular inflammation and foam cell formation by targeting HBP-1 in atherogenesis. Scientific reports 60 28935967
2019 Blocking lncRNA H19-miR-19a-Id2 axis attenuates hypoxia/ischemia induced neuronal injury. Aging 57 31170091
2023 SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis. The Journal of clinical investigation 54 36749634
2015 5-lipoxygenase is a direct target of miR-19a-3p and miR-125b-5p. Journal of immunology (Baltimore, Md. : 1950) 49 25589070
2006 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. International immunology 47 16410313
2019 Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer immunology research 46 31431433
2021 MiR-19a-3p Suppresses M1 Macrophage Polarization by Inhibiting STAT1/IRF1 Pathway. Frontiers in pharmacology 45 34017248
2015 Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry. Part B, Clinical cytometry 45 26130131
2009 alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. Journal of neuroimmunology 45 19345424
2015 Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer. Oncotarget 44 26041879
2013 miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. Asian Pacific journal of cancer prevention : APJCP 44 23621248
1998 New tools in an old trade: CS1 pilus morphogenesis. Molecular microbiology 44 10094617
1994 CooC and CooD are required for assembly of CS1 pili. Molecular microbiology 43 7915003
2015 Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression. PloS one 42 26367773
2022 CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia 41 35422095
2020 Circ-EPB41L5 regulates the host gene EPB41L5 via sponging miR-19a to repress glioblastoma tumorigenesis. Aging 41 31905344
2004 Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. European journal of immunology 41 15368295
2016 MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. Leukemia & lymphoma 40 27830963
2015 MiR-19a regulates PTEN expression to mediate glycogen synthesis in hepatocytes. Scientific reports 40 26111969
2008 Regulation of NK cell activity by 2B4, NTB-A and CRACC. Frontiers in bioscience : a journal and virtual library 40 17981603
2018 Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 39 30410677
2012 A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. British journal of haematology 39 22533610
2020 CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry. Part B, Clinical cytometry 35 33017079
2019 Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nature communications 35 30710089
2015 MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. World journal of gastroenterology 33 25914465
2021 Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2. International journal of biological sciences 32 34512170
2019 MiR-19a enhances cell proliferation, migration, and invasiveness through enhancing lymphangiogenesis by targeting thrombospondin-1 in colorectal cancer. Biochemistry and cell biology = Biochimie et biologie cellulaire 32 31199884
2021 LncRNA-H19 Drives Cardiomyocyte Senescence by Targeting miR-19a/socs1/p53 Axis. Frontiers in pharmacology 31 33664669
2018 MiR-19a negatively regulated the expression of PTEN and promoted the growth of ovarian cancer cells. Gene 31 29783075
2019 Circ_ORC2 enhances the regulatory effect of miR-19a on its target gene PTEN to affect osteosarcoma cell growth. Biochemical and biophysical research communications 30 31103262
2014 MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. International journal of clinical and experimental pathology 30 25400827
2012 Role of the NK cell-activating receptor CRACC in periodontitis. Infection and immunity 29 23250953
2020 Exosomal miR-19a from adipose-derived stem cells suppresses differentiation of corneal keratocytes into myofibroblasts. Aging 28 32112551
2020 Glycine Improves Ischemic Stroke Through miR-19a-3p/AMPK/GSK-3β/HO-1 Pathway. Drug design, development and therapy 28 32546967
2018 miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis. Cancer letters 28 29702193
2013 BB0347, from the lyme disease spirochete Borrelia burgdorferi, is surface exposed and interacts with the CS1 heparin-binding domain of human fibronectin. PloS one 28 24086600
2020 First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 31969330
2017 MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 26 28475001
2017 Menopause and adipose tissue: miR-19a-3p is sensitive to hormonal replacement. Oncotarget 26 29416771
2024 Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy. Cancer research 25 38484085
2016 MiR-19a promotes cell proliferation and invasion by targeting RhoB in human glioma cells. Neuroscience letters 25 27329239
2015 Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Expert review of hematology 25 26070331
2017 Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy 24 28483281
2010 The CS1 segment of fibronectin is involved in human OSCC pathogenesis by mediating OSCC cell spreading, migration, and invasion. BMC cancer 24 20579373
2022 Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway. BMC cancer 23 36476239
2021 miR-19a/b promote EMT and proliferation in glioma cells via SEPT7-AKT-NF-κB pathway. Molecular therapy oncolytics 23 33614912
2021 MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer. Oncogene 23 33674746
2023 ALKBH5 mediates silica particles-induced pulmonary inflammation through increased m6A modification of Slamf7 and autophagy dysfunction. Journal of hazardous materials 22 37827106
2018 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer. Clinical immunology (Orlando, Fla.) 21 30347240
2024 Bioengineer mesenchymal stem cell for treatment of glioma by IL-12 mediated microenvironment reprogramming and nCD47-SLAMF7 mediated phagocytosis regulation of macrophages. Exploration (Beijing, China) 20 39713206
2018 Shenfu Injection attenuates rat myocardial hypertrophy by up-regulating miR-19a-3p expression. Scientific reports 20 29549288
2013 PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis research & therapy 20 24299175
1998 Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A. Anticancer research 20 9703885
2022 SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity. Journal of neuroinflammation 19 36199066
2018 Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. Expert review of hematology 19 29582696
2015 The alternatively spliced fibronectin CS1 isoform regulates IL-17A levels and mechanical allodynia after peripheral nerve injury. Journal of neuroinflammation 19 26337825
1993 Role of the CS1 adhesion motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node endothelium. Annals of the rheumatic diseases 19 8239762
2022 Antagonizing microRNA-19a/b augments PTH anabolic action and restores bone mass in osteoporosis in mice. EMBO molecular medicine 18 36193848
2020 LncRNA HAGLR accelerates femoral neck fracture healing through negatively regulating miRNA-19a-3p. European review for medical and pharmacological sciences 18 32373944
2016 Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Therapeutic advances in hematology 18 27695618
2021 Osteosarcoma Cell-Derived Small Extracellular Vesicles Enhance Osteoclastogenesis and Bone Resorption Through Transferring MicroRNA-19a-3p. Frontiers in oncology 17 33842319
2020 MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. Journal of Cancer 17 32201518
2000 RNA-binding characteristics of the chloroplast S1-like ribosomal protein CS1. Nucleic acids research 17 10954599
2021 Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 16 34680541
2020 LncRNA NEAT1 promotes cardiac hypertrophy through microRNA-19a-3p/SMYD2 axis. European review for medical and pharmacological sciences 16 32096186
2020 Association of circulating SLAMF7+Tfh1 cells with IgG4 levels in patients with IgG4-related disease. BMC immunology 16 32487061
2000 Regulation of CS1 fibronectin expression and function by IL-1 in endothelial cells. Cellular immunology 16 10716877